Skip to content

Supernus Pharmaceuticals

US · SUPN #2636 by market cap Listed 1970
28.61 +0.26 +0.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:48

Valuation each multiple against its own 5-year range

P/B ratio 5.81 Expensive vs history 100th percentile
5-year average 2.10 · #56 of 68 in Drug Manufacturers - Specialty & Generic
P/E ratio -39.11 Cheap vs history 20th percentile
5-year average 84.23 · forward 80.30
P/S ratio 7.14 Expensive vs history 100th percentile
5-year average 3.03 · forward 2.63 · #61 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Supernus Pharmaceuticals (SUPN) 5.94B -37.64 5.59 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value32.15 Economic moatNone UncertaintyHigh

Trading 12.4% below Morningstar's fair value estimate.

Fair value

Supernus Inc is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 8% discount to our quantitative fair value estimate of $32.15 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 69.7% falls in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are cheap.

Conversely, the firm's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, lies in the top 40% globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 16:48:01 · For reference only, not investment advice and not tailored to your situation.

Supernus Pharmaceuticals discussion 0 comments

Add a comment